Explainer
Kratom and 7-OH explained: risks, legal status and DEA scheduling
Kratom is a Southeast Asian tree whose leaves can produce opioid-like and stimulant-like effects; it is sold widely in the US but FDA has approved no use for it.[1][2][3] 7-OH is a minor kratom alkaloid with much stronger opioid-receptor potency, now sold in concentrated products; FDA asked DEA to schedule it in July 2025.[4][5] In October 2026 DEA issued a notice of intent to temporarily place 7-OH above a set threshold in Schedule I.[6]
This page is general information, not medical advice. It does not give amounts or instructions for use. If you use kratom or 7-OH and want to stop, or are worried about withdrawal, talk to a clinician.
For confidential help with substance use, call the SAMHSA National Helpline at 1-800-662-HELP (4357) or visit FindTreatment.gov.[7] For a possible poisoning, US poison control is 1-800-222-1222; in an emergency, call 911.[8]
Kratom is a plant product sold in the US online and in stores.[1] Since 2025 federal regulators have focused on concentrated products made from one of its compounds, 7-hydroxymitragynine (7-OH), rather than on natural kratom leaf.[5] This page explains both, what is known about their risks, and where federal action stands.
What kratom is
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia, and products made from its leaves are sold in the US online and in stores.[1] NIDA says kratom can produce both opioid-like and stimulant-like effects.[2] About 1.7 million Americans aged 12 and older used it in 2021, according to the National Survey on Drug Use and Health.[9]
People report using kratom to self-treat pain, anxiety, depression, opioid use disorder and opioid withdrawal.[3] FDA has approved no use for kratom, and no kratom drug products are legally marketed.[3][10] NIDA says much is still unknown about kratom’s short- and long-term health and safety effects, and it supports research on kratom’s potential medicinal uses.[11]
Known risks of kratom
FDA warns consumers not to use kratom because of the risk of serious adverse events, including liver toxicity, seizures and substance use disorder.[12] Deaths have been associated with kratom in rare cases, but FDA and NIDA say nearly all involved other drugs or contaminants, so kratom’s own contribution is unclear.[13] FDA is also aware of newborns showing withdrawal signs (neonatal abstinence syndrome) after prolonged kratom exposure before birth, and has warned about products contaminated with Salmonella or heavy metals.[14]
What 7-OH is and why regulators focus on it
7-OH occurs naturally in kratom, but makes up less than 2% of the leaf’s alkaloids.[4] FDA says it has substantially greater mu-opioid receptor potency than mitragynine, kratom’s main alkaloid, and than morphine.[4] DEA notes that 7-OH can be made from mitragynine in a one-step chemical reaction.[15]
FDA said in July 2025 that concentrated 7-OH products were easy to buy online and in gas stations, corner stores and vape shops, including forms such as fruit-flavored gummies and ice cream cones that may appeal to children.[16] There are no FDA-approved 7-OH drugs, and 7-OH is not lawful in dietary supplements or conventional foods.[17] DEA has cited 165 poison center exposure cases involving 7-OH from January to July 2025; among cases involving 7-OH alone, 35% resulted in serious health problems.[18]
Federal and state action
| Date | Action |
|---|---|
| June 2025 | FDA sends warning letters to seven companies selling 7-OH products[16] |
| 29 Jul 2025 | FDA recommends scheduling certain 7-OH products, not natural kratom leaf[5] |
| Jul 2026 | DEA notice of intent to temporarily schedule 7-OH above a threshold[19] |
| 26 Aug 2026 | Temporary order puts three related compounds, including mitragynine pseudoindoxyl, in Schedule I until August 2028[20] |
| 14 Oct 2026 | DEA withdraws the July notice and issues a new one, with a threshold recommended by HHS on 8 October[6] |
DEA, not FDA, has the final say on scheduling.[21] The October 2026 notice covers 7-OH and mitragynine pseudoindoxyl above a specified threshold; DEA said the threshold would let some products stay on sale but that neither it nor HHS had found below-threshold levels safe.[6] The Schedule I controls would apply once DEA issues the temporary order itself.[22]
FDA said its 7-OH recommendation was not focused on natural kratom leaf products, and NIDA says kratom products remain legal in many areas while agencies review the evidence.[5][23] States vary: DEA notes that 19 states have passed Kratom Consumer Protection Act model laws, and some cap 7-OH as a share of total alkaloids.[24] FDA separately says kratom cannot lawfully be sold as a drug, dietary supplement or food additive.[10]
Federal scheduling of 7-OH was still in progress when this page was written. Check the Federal Register for whether DEA has issued the temporary order.
Read next
Next in the crash course
Gambling disorder explained: signs, how common it is and getting help
What gambling disorder is, its warning signs, how many people it affects in the US and worldwide, the harms it causes and where to find help.
Questions readers ask
What is kratom?
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia. Products made from its leaves are sold in the US online and in stores, and NIDA says they can produce both opioid-like and stimulant-like effects.[1][2]
What is 7-OH?
7-hydroxymitragynine (7-OH) is a naturally occurring kratom alkaloid that makes up less than 2% of the leaf's alkaloids. FDA says it is far more potent at opioid receptors than kratom's main alkaloid, and DEA says it can be made from that alkaloid in a one-step chemical reaction.[4][15]
Is kratom legal?
NIDA says kratom products are currently legal in many areas. FDA says kratom cannot lawfully be sold as a drug, dietary supplement or food additive, and some states regulate it.[23][10][24]
Is 7-OH being banned?
FDA recommended scheduling 7-OH in July 2025. On 14 October 2026 DEA issued a notice of intent to temporarily place 7-OH and a related compound above a specified threshold in Schedule I; the controls apply once a temporary order is issued.[5][6][22]
Sources
· 24 claims from 3 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia whose leaf products are sold in the US online and in stores. confirmedas of 2026-11-07
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
- [2]
NIDA says kratom can produce both opioid-like and stimulant-like effects. confirmedas of 2026-11-07
- Kratom · National Institute on Drug Abuse · Primary source · Highlights (retrieved 2026-11-07)
- [3]
People report using kratom to self-treat pain, anxiety, depression, opioid use disorder and opioid withdrawal, though FDA has approved no use for kratom. confirmedas of 2026-11-07
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
- Kratom · National Institute on Drug Abuse · Primary source · Highlights (retrieved 2026-11-07)
- [4]
7-hydroxymitragynine (7-OH) occurs naturally in kratom but makes up less than 2% of the leaf's alkaloids, and FDA says it has substantially greater mu-opioid receptor potency than mitragynine and than morphine. confirmedas of 2026-11-07
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
- [5]
On 29 July 2025 FDA recommended scheduling certain 7-OH products under the Controlled Substances Act, saying it was targeting concentrated 7-OH and not natural kratom leaf products. confirmedas of 2026-11-07
- FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers · U.S. Food and Drug Administration · Primary source · 2025-07-29 · First paragraph (July 29, 2025) (retrieved 2026-11-07)
- FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers · U.S. Food and Drug Administration · Primary source · 2025-07-29 · First paragraph (retrieved 2026-11-07)
- [6]
After an 8 October 2026 HHS letter recommending a new threshold, DEA on 14 October 2026 withdrew its July notice and issued a new notice of intent to temporarily schedule 7-OH and mitragynine pseudoindoxyl above that threshold, saying the threshold would let certain products stay on the market but that neither agency had found below-threshold levels safe. confirmedas of 2026-11-07
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Summary (retrieved 2026-11-07)
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Summary (retrieved 2026-11-07)
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Summary (retrieved 2026-11-07)
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Summary (retrieved 2026-11-07)
- [7]
The SAMHSA National Helpline, 1-800-662-HELP (4357), and FindTreatment.gov give US referrals to substance use and mental health treatment programs. confirmedas of 2026-11-07
- Research Topics · National Institute on Drug Abuse · Primary source · In an emergency? Need treatment? (retrieved 2026-11-07)
- [8]
In the US, poison control can be reached at 1-800-222-1222, and people in immediate danger should call 911. confirmedas of 2026-11-07
- Research Topics · National Institute on Drug Abuse · Primary source · In an emergency? Need treatment? (retrieved 2026-11-07)
- Research Topics · National Institute on Drug Abuse · Primary source · In an emergency? Need treatment? (retrieved 2026-11-07)
- [9]
About 1.7 million Americans aged 12 and older used kratom in 2021, according to the National Survey on Drug Use and Health as cited by FDA. confirmedas of 2026-11-07
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
- [10]
FDA says no kratom drug products are legally on the US market and that kratom cannot lawfully be sold as a dietary supplement or added to conventional food. confirmedas of 2026-11-07
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · Introduction (retrieved 2026-11-07)
- [11]
NIDA says much is still unknown about the short- and long-term health and safety effects of kratom, and it supports and conducts research on kratom's potential medicinal uses. confirmedas of 2026-11-07
- [12]
FDA warns consumers not to use kratom because of the risk of serious adverse events including liver toxicity, seizures and substance use disorder. confirmedas of 2026-11-07
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · What can happen if a person uses kratom? (retrieved 2026-11-07)
- [13]
FDA and NIDA say a small number of deaths have been associated with kratom, nearly all involving other drugs or contaminants, so kratom's contribution is unclear. confirmedas of 2026-11-07
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · What can happen if a person uses kratom? (retrieved 2026-11-07)
- Kratom · National Institute on Drug Abuse · Primary source · Highlights (retrieved 2026-11-07)
- [14]
FDA is aware of neonatal abstinence syndrome cases after prolonged kratom exposure before birth and has warned about kratom products contaminated with Salmonella or heavy metals. confirmedas of 2026-11-07
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · What can happen if a person uses kratom? (retrieved 2026-11-07)
- FDA and Kratom · U.S. Food and Drug Administration · Primary source · What can happen if a person uses kratom? (retrieved 2026-11-07)
- [15]
DEA says 7-OH can be made from mitragynine, kratom's main alkaloid, in a one-step chemical reaction. confirmedas of 2026-11-07
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Background (retrieved 2026-11-07)
- [16]
FDA said concentrated 7-OH products were sold online and in gas stations, corner stores and vape shops, including forms that may appeal to children such as fruit-flavored gummies, and in June 2025 it sent warning letters to seven companies. confirmedas of 2026-11-07
- FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers · U.S. Food and Drug Administration · Primary source · 2025-07-29 · Press release body (retrieved 2026-11-07)
- FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers · U.S. Food and Drug Administration · Primary source · 2025-07-29 · Press release body (retrieved 2026-11-07)
- FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers · U.S. Food and Drug Administration · Primary source · 2025-07-29 · Press release body (retrieved 2026-11-07)
- [17]
FDA says there are no FDA-approved 7-OH drugs, and 7-OH is not lawful in dietary supplements or conventional foods. confirmedas of 2026-11-07
- FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers · U.S. Food and Drug Administration · Primary source · 2025-07-29 · Press release body (retrieved 2026-11-07)
- [18]
DEA cited 165 poison center exposure cases involving 7-OH from January to July 2025; among cases involving 7-OH alone, 35% resulted in serious health problems. confirmedas of 2026-11-07
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Factor 6 (retrieved 2026-11-07)
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Factor 6 (retrieved 2026-11-07)
- [19]
In July 2026 DEA published a notice of intent to temporarily place 7-OH above a specified threshold in Schedule I. confirmedas of 2026-11-07
- Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-07-06 · Summary (retrieved 2026-11-07)
- [20]
A DEA temporary order placed three 7-OH-related substances, mitragynine pseudoindoxyl, MGM-15 and MGM-16, in Schedule I from 26 August 2026 until 26 August 2028. confirmedas of 2026-11-07
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-08-26 · Summary (retrieved 2026-11-07)
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-08-26 · Dates (retrieved 2026-11-07)
- [22]
DEA's October 2026 document is a notice of intent; the Schedule I controls on 7-OH above the threshold would apply once a temporary order is issued. confirmedas of 2026-11-07
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Summary (retrieved 2026-11-07)
- [23]
NIDA says kratom products are currently legal in many areas while US and international agencies review the evidence. confirmedas of 2026-11-07
- [24]
DEA notes that 19 states have enacted Kratom Consumer Protection Act model legislation, and some states cap 7-OH as a share of total alkaloid content. confirmedas of 2026-11-07
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Background, state actions (retrieved 2026-11-07)
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I · Federal Register (Drug Enforcement Administration) · Primary source · 2026-10-14 · Background, state actions (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Jan 7, 2027.
Cite this page
"Kratom and 7-OH explained: risks, legal status and DEA scheduling." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/kratom-and-7-oh-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.